Birkenfeld, September 7, 2006
STRATEC Biomedical Systems AG today published an ad-hoc announcement (statutory company announcement) with its sales and earnings forecast for the 2006 and 2007 financial years. Pursuant to this announcement, the company assumes that it will be possible to increase its sales for 2006 to between Euro 65 million and Euro 68 million (sales corridor) and for 2007 to between Euro 75 million and Euro 78 million (sales corridor) and to increase its earnings before tax (EBT) to between Euro 10.5 million and Euro 11 million in 2006 (earnings corridor) and to between Euro 14 million and Euro 15 million in 2007 (earnings corridor).
In view of the considerable increase in the basis for the 2007 financial year, based on its current planning the company expects to achieve an annual average growth rate (CAGR) of more than 11% in the case of sales and of more than 16% for earnings before tax (EBT) from 2008 up to and including 2010.
As a result of the basis effect (higher basis in 2007) and the shifting of the period under consideration by one year from 2008 the average annual growth rate (CAGR) for our key sales and earnings figures is lower in percentage terms, yet higher in absolute terms, in the long-term forecast (for 2008 to 2010) than in the forecast published in December 2005 (for 2007 to 2009). Assuming that the targets stated in our long-term forecast are met, the average annual growth rate (CAGR) reported by the STRATEC Group for the financial years from 2000 to 2010 would amount to more than 25% in the case of sales and to more than 34% in the case of earnings before tax (EBT).
The forecast for 2008 to 2010 takes only limited account of the conclusion of outstanding new development and supply agreements for new analyzer system families with existing and new customers.
The new budget figures are considerably higher than the internal budget targets most recently forecast in December 2005. These forecast that the sales for the 2006 financial year would increase to Euro 55 million to Euro 59 million (sales corridor) and that earnings before tax (EBT) would rise to Euro 8.3 million to Euro 9.2 million (earnings corridor). An average annual growth rate (CAGR) of more than 15% in the case of sales and of more than 22% for earnings before tax (EBT) was forecast for the subsequent 2007 to 2009 financial years.
The annual average growth (CAGR) reported for the financial years from 2000 up to and including 2005 amounted to more than 32% in terms of sales and to more than 40% in the case of earnings before tax (EBT).
STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart Stock Exchange and on other exchanges.
The STRATEC Group comprises the listed holding company "STRATEC Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen", "Robion" and "Sanguin".
Further information can be obtained from:
STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 E-Mail: email@example.com
--- End of Message --- WKN: 728900; ISIN: DE0007289001; Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in Börse Stuttgart, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf;
Viðskiptablaðið er 25 ára og af því tilefni býðst nýjum áskrifendum að kaupa áskrift á 50% afslætti.
Afmælisverðið er aðeins 2.500 krónur.
Tilboðið er fyrir nýja áskrifendur. Núverandi áskrifendur geta bætt við sig áskrift á þessu verði. Gildir í 4 mánuði. Áskrifendur fá Viðskiptablaðið, Frjálsa verslun og Fiskifréttir sent ásamt vefaðgangi að vb.is og fiskifrettir.is